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All the original references were provided by the Nobel Laureate Youyou Tu. The publication process involving the discovery of
artemisinin was collected and sorted by her ﬁrst PhD student, Associate Professor Man-Yuan Wang. Through the publication of this
article, the journal expects to provide a reference to the scientists who dedicated to the research of artemisinin, especially those who
are interested in the discovery process of artemisinin.1. Introduction
Diseases caused by parasites have been puzzling humans for
thousands of years, remaining one of the major problems in the
ﬁeld of global health. Mosquito-borne tropical parasitic diseases
are kinds of diseases with serious harmfulness which especially
affect populations in the world's poorest areas and also turn to be
a huge barrier hindering mankind's health and happiness from
improvement. In 2015, William C. Campbell, Satoshi Omura
and Youyou Tu won the Nobel Prize in Physiology or Medicine
owing to their revolutionary contributions to prevent and treat
the most destructive parasitic diseases. The Nobel Prize in
Physiology or Medicine is a global important award with great
inﬂuence in the biological sciences. The 2015 Nobel Prize in
Physiology or Medicine has further led to wide discussions
among tropical biomedical research workers around the world.
The awards of the Nobel Prizes often involve a time delay.
They can be awarded to the scientiﬁc achievements which were
made several years, more than a decade or even decades ago.
The scientiﬁc achievement of Youyou Tu was made decades
ago. Her scientiﬁc research was conducted in the 1970s. Since
Youyou Tu is the ﬁrst Chinese Scientist winning this global
prestigious award, when the news was announced, an extensive
discussion arose at hometown and abroad. From another point of
view, after Youyou Tu won the Lasker-DeBakery Clinical
Medical Research Award in 2011, researchers have paid more
and more attention to artemisinin (qinghaosu) and the treatment
of malaria. Therefore, domestic and overseas scientists have
published a lot of related reviews which promote the under-
standing of the discovery and development of artemisinin [1–5].
Because of the special background, there were incompre-
hension and controversies in assessment of the discoveryprocess of artemisinin. The incomprehension and controversies
even exist after Youyou Tu won the Nobel Prize, which reﬂects
that people give a lot of attention to important scientiﬁc and
technological inventions and their social-cultural impacts and
also demonstrates that many scientiﬁc researchers are still not
clear of the concrete ownership of the main achievement of
artemisinin project. Youyou Tu is the only rewarded person of
the scientiﬁc achievement of artemisinin project who was chosen
to won the 2015 Nobel Prize in Physiology or Medicine, which
triggers the cognitive desire of people both here and abroad
towards how the mainstream academic community evaluates the
individual contribution of the achievement of artemisinin proj-
ect. Only one key documental information (“Tu et al., Yao Xue
Xue Bao (1981) 16, 366–370 (Chinese)”) was listed in the
Award Bulletin. The Nobel committee did not give any other
information about the achievement evaluation. “The main sci-
entiﬁc research was carried out in 1970s”, “Many artemisinin-
related articles has been published before 1981” and “Related
articles were published anonymously or in the name of a team”
reminded many people of why the article in 1981 of Youyou Tu
was chosen as the key reference for her Nobel Prize. Up to now,
there is no article studying the public publishing process of the
scientiﬁc achievement of artemisinin. In this study, based on the
related original references, the author strived to restore the
process and expected to answer those related questions. In 1985,
D. L. Klayman published an article named “Qinghaosu (arte-
misinin): an antimalarial drug from China” in Science [6]. After
that, the handling method of most articles related to the
discovery of artemisinin agreed with that article. That was a
general statement: the speciﬁc inventor of the new anti-malaria
therapy was not clear. Hence, the study aimed to stress the
publication process involving the discovery of artemisinin
before 1985 so as to provide more reference information to those
related personnel.cle under the CC BY-NC-ND license (http://
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the prevention and treatment of malaria (in 1972)
From August 1972 to October 1972, artemisinin extracts were
ﬁrstly used in clinical trials by the research team of Youyou Tu.
Local people with strong immunity and external people without
immunity were selected. The types of malaria were from Plas-
modium vivax (P. vivax) to Plasmodium falciparum
(P. falciparum). A total of 21 clinical anti-malaria cases were
observed. There were 11 cases infected by P. vivax, 9 cases by
P. falciparum and 1 case by mixed species of Plasmodium. The
clinical results were pretty satisfactory. The average deferves-
cence time of P. vivax cases was 19 h, while the average defer-
vescence time of P. falciparum patients was 36 h. The species of
Plasmodium all turned negative. The related results were collected
andmanaged bymalaria prevention and controlling organizations
of Guangdong. The content in the red box in Figure 1 is the ﬁrst
publication of the curative effect of artemisinin extracts on clinical
anti-malaria. It was conﬁrmed that anti-malaria research of arte-
misinin in Beijing (Scientiﬁc team of Youyou Tu, Institute of
Chinese Materia Medica, China Academy of Chinese Medical
Sciences) had made a great progress.
3. Kexue Tongbao (in 1977)
The chemical structure of artemisinin was issued by Kexue
Tongbao in 1977 [7], which was accomplished by researchers of
the scientiﬁc team of Youyou Tu and colleagues of Institute of
Biophysics of Chinese Academy of Sciences and Shanghai
Institute of Organic Chemistry of Chinese Academy of
Sciences. The publication application was reported to the
Ministry of Health. And after approved, the paper was
submitted to Kexue Tongbao on 20th February 1976. Then the
paper (A new sesquiterpene lactone-Qinghaosu) was published
in issue No. 3 in 1977. Considering the conﬁdentiality require-
ment of Chinese military force missions, in order to preventFigure 1. A copy of a paragraph of Communication on Malaria Controlling Re
on 5th November 1972.further development of medical use by other countries, the paper
was published in the name of “the Collaborating Group of
Qinghaosu Structure”. The paper only reported the chemical
structure and partial physical and chemical properties of arte-
misinin, but its excellent anti-malaria activity was not reported.
The concrete content was shown in Figure 2. After the publi-
cation, the related contents have been indexed by Chemical
Abstracts (C.A. 1977, 87, 98788g), which promoted the process
that artemisinin was concerned by international peers. The
related reference demonstrated that the Institute of Chinese
Materia Medica of China Academy of Chinese Medical Sciences
was the main institution which was in charge of the relative
research achievements.
4. Yao Xue Tong Bao (in 1979), Acta Chimica Sinica
(in 1979), Chinese Medical Journal (in 1979)
In November 1978, based on the early preliminary meeting
(Xiangshan, Beijing), the National Leading Group Ofﬁce of
Malaria Prevention and Controlling Research hold a conference
about artemisinin assessment in Yangzhou, Jiangsu Province.
Among early-stage artemisinin-related conferences, this confer-
ence ﬁrstly invited media representatives, promoting the pub-
licity of the related achievement. According to the outward
information of the conference, over 40 units from ten provinces,
cities and municipalities participated in the clinical trials. A total
of 6555 cases were tested (529 cases were completed by China
Academy of Chinese Medical Sciences), and 2099 cases of them
were artemisinin preparations. In practical clinical work, many
kinds of dosage forms were used such as solid dispersions,
tablets, capsules, injections, suppositories and so on. Clinical
cases included malaria infected by P. vivax or P. falciparum and
cerebral malaria. After the conference, all relevant units and
researchers published the related research achievement to make
the research progress of artemisinin against malaria known to the
public.search issued by the National Leading Group Ofﬁce for Malaria Controlling
Figure 2. A copy of the publication information on “A new sesquiterpene lactone–qinghaosu” (Kexue Tongbao 1977; 22(3): 142) [7].
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drug qinghaosu”, “Chemical structure and reaction of arteannuin”,
“Antimalarial studies on qinghaosu” and so forth, have reported
the research achievement of the chemical structure, physical and
chemical properties, structure study, antimalarial activity, phar-
macology and toxicology of artemisinin in Chinese or English.
These papers were signed collectively and the ﬁrst afﬁliation was
the Institute of Chinese Materia Medica, China Academy of Chi-
nese Medical Sciences. The concrete contents were shown in
Figure 3 [8–10]. The publication of this batch of papers has
promoted the international recognition degree of the anti-malaria
drug artemisinin studied by Chinese scientists, which have laid
the foundation of the further internationalization of the drug.Figure 3. A copy of the publication information on “Studies on new antimalari
structure and reaction of arteannuin” (Acta Chimica Sinica 1979; 37(2): 129–14
92(12): 811–816) [10].5. ZhongYaoTongBao (in 1981),ActaPharmaceutica
Sinica (in 1981)
In 1981, with the change of social environment, the research
results of Artemisia annua L. (A. annua) and artemisinin were
further arranged and issued by the scientiﬁc research group of
Youyou Tu with a personal signature. Zhong Yao Tong Bao
published an article entitled “Studies on the constituents of A.
annua L. and derivatives of qinghaosu (brief report)”, providing
a summary of the speciﬁc development of the chemical com-
ponents of A. annua, the research results on the artemisinin
derivatives and preliminary structure–activity relationship [11].
Acta Pharmaceutica Sinica also published an article entitledal drug qinghaosu” (Yao Xue Tong Bao 1979; 14(2): 49–53) [8], “Chemical
3) [9], “Antimalaria studies on qinghaosu” (Chinese Medical Journal 1979;
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the extraction, separation and structural identiﬁcation of
artemisinin and presenting the chemical constituents in
A. annua including sesquiterpenes arteannuin A, arteannuin B,
arteannuin C and ﬂavone, coumarin, essential oil and other
chemical constituents in detail [12]. Youyou Tu served as the
ﬁrst author of these two articles. The article published by Acta
Pharmaceutica Sinica was selected as the key literature by the
Nobel Committee. The article information was shown in
Figure 4.
6. Journal of Traditional Chinese Medicine (in 1982)
and Planta Medica (in 1982)
In October 1981, in the 4th meeting of the scientiﬁc working
group on the chemotherapy of malaria, an international confer-
ence in the name of “special conference on qinghaosu” was held
by the United Nations Development Programme/the World
Bank/the World Health Organization (WHO) special programe
for research and training in malaria chemotherapy group of
tropical diseases in Beijing. The Chinese artemisinin research
and development group made a systematic introduction of the
related research at the meeting. After that, L. J. Bruce-Chwatt, a
British expert, simply introduced the research development of
artemisinin with an article “Qinghaosu: a new antimalarial” in
British Medical Journal [13]. Related papers of Chinese
specialists were published at the beginning of 1982 in the
name of “China cooperative research group on qinghaosu andFigure 4. A copy of the publication information on “Studies on the constitue
(Zhong Yao Tong Bao 1981; 6(2): 31) [11], “Studies on the constituents of Artits derivatives as antimalarials” in Journal of Traditional
Chinese Medicine [14], which included six papers: “Chemical
studies on qinghaosu (artemisinine)”, “The chemistry and
synthesis of qinghaosu derivatives”, “Antimalarial efﬁcacy and
mode of action of qinghaosu and its derivatives in
experimental models”, “Metabolism and pharmacokinetics of
qinghaosu and its derivatives”, “Studies on the toxicity of
qinghaosu and its derivatives” and “Clinical studies on the
treatment of malaria with qinghaosu and its derivatives”. As
for the signature information of these papers, the Institute of
Chinese Materia Medica of China Academy of Chinese
Medical Sciences was presented to be the major unit of the
discovery of artemisinin. After the international meeting,
Planta Medica sent a manuscript invitation to Youyou Tu's
team [15]. In 1982, an article titled “Studies on the constituents
of A. annua L. Part II” was published and Youyou Tu is the
ﬁrst author. In this article, the related information of the
extraction, separation and structural identiﬁcation of the
chemical constituents of sesquiterpenoids, ﬂavonoids and
coumarins which were isolated from A. annua L. is introduced
in English. The concrete article information was shown in
Figure 5.
7. General considerations
Ever since artemisinin and its derivatives came into being,
which have played a key role in saving people from malaria.
Artemisinin and its derivatives used in clinic mainly include
artemisinin, dihydroartemisinin, artemether, arteether andnts of Artemisia annua L. and derivatives of qinghaosu (concise report)”
emisia annua L. I” (Acta Pharmaceutica Sinica 1981; 16(5): 366–370) [12].
Figure 5. A copy of the publication information on “Chemical studies on qinghaosu (artemisinine)” (Meeting reports of the 4th meeting of the scientiﬁc
working group on the chemotherapy of malaria in Beijing in 1981 and Journal of Traditional Chinese Medicine 1982; 2(1): 3–8) [14], “Studies on the
constituents of Artemisia annua L. Part II” (Planta Medica 1982; 44(3): 143–5) [15].
Figure 6. Summary of the work done mainly by the research team in China
Academy of Traditional Chinese Medicine (boxes in blue background), the
work completed by the collaboration between the Institute of Chinese
Materia Medica and other units (boxes in transitioning from blue to white),
and the work completed by the collaboration between Other Research
Teams across the Nation (boxes in white).
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included the following artemisinin-based drugs: artemether bulk
drugs and injections, artemisinin bulk drugs, tablets and cap-
sules, arteether bulk drugs and injections, dihydroartemisinin
bulk drugs and tablets, as well as artesunate bulk drugs and
tablets. The WHO has begun to recommend artemisinin-based
combination therapies (ACTs) in 2001 [16]. In 2006, ACTs
combinatorial drugs were contained in the ﬁrst version of
Guidelines for the Treatment of Malaria made by WHO. In
2015, 5 ACTs were recommended in the third version. They
were artemether + lumefantrine, artesunate + amodiaquine,
artesunate + meﬂoquine, artesunate + sulfadoxine/
pyrimethamine and dihydroartemisinin + piperaquine,
respectively. In recent years, the value of ACTs becomes a
highlighted topic. According to data of WHO, the global death
rate of malaria from 2000 to 2013 decreased by 47%. The
death rate in African areas where the death toll of malaria
accounted for 90% of the world's total number also decreased
by 54% [17]. Artemisinin-based drugs have saved millions of
malaria patients around the world.
The scientiﬁc research achievement of artemisinin was
accomplished in a complicated social culture environment. There
were many afﬁliations and people participating in it. Just like
what Youyou Tu evaluated, artemisinin was a gift of traditional
Chinese medicine to people around the world, which is of great
importance to the prevention and treatment of infectious diseases
such as malaria and the maintenance of people's health. The
discovery of artemisinin is a successful example for collective
exploration of traditional Chinese medicine. Therefore, the
award is a collective honor for those Chinese scientists. The
achievement of artemisinin belongs to every person of the sci-
entiﬁc team. A simple summary of the related work was shown
in Figure 6. Terms in boxes in blue background were accom-
plished by the anti-malaria team of Institute of Chinese Materia
Medica, China Academy of Chinese Medical Sciences, terms in
boxes in white background were accomplished by othercooperative teams, and terms in boxes in transiting from blue to
white were ﬁnished by the institute and other cooperative groups.
The invention right of artemisinin has remained disputable for
years. From the aspect of literature publications, the Institute of
Chinese Materia Medica, China Academy of Chinese Medical
Sciences should be the main research unit and Youyou Tu should
be the main creator. There are also some indirect evidences
supporting the idea, such as, the order and speciﬁc illustration of
the certiﬁcate of the invention. The concrete information was
shown in Figure 7. Also, the article titled “The development of
the antimalarial drugs with new type of chemical structure:
qinghaosu and dihydroqinghaosu” was published in Southeast
Asian Journal of Tropical Medicine and Public Health in 2004 by
Youyou Tu herself [18].
Figure 7. A copy of the invention certiﬁcate for artemisinin and Youyou Tu.
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how to estimate scientiﬁc research achievement has raised more
and more attentions in the international scientiﬁc community at
present. In general, scientiﬁc researchers disseminate their
research achievement by issuing research papers, which can not
only be an effective way to promote the application of the
achievement by communicating with their counterparts, but also
be an academic honor for those authors. Artemisinin drugs have
been widely used for over ten years in the whole world, and their
research, social value and the achievement of their creators have
been agreed by many academic communities and scientiﬁc
workers. However, the research achievement of artemisinin
project is limited by speciﬁc social historical conditions and
divorced from the paradigm and course of the publications of
mainstream scientiﬁc researches, which makes it difﬁcult to be
estimated. The author held an idea that the difﬁculty, to a certain
degree, delayed the Nobel Prize of Youyou Tu. Australian sci-
entists Barry J. Marshall and J. Robin Warren were honored with
the Nobel Prize in Physiology or Medicine in 2005 for the dis-
covery of Helicobacter pylori and its pathogenesis for peptic
ulcer disease. Their study was originating from 1979. The related
research papers were all published gradually in academic jour-
nals with personal signatures by classic route transmissions of
academic achievements, which further transmit and expand the
research achievements. The author insists that the reason why
they won Nobel Price 10 years earlier than Youyou Tu must
have something to do with this mode which is conductive to
achievement evaluation.
Ever since Youyou Tu started studying anti-malarial drugs
from 1969, she has studied the reasonable application of
artemisinin-based drugs, development of drug resistance,
expansion of indications and development of new ACTs drugs.
Besides, she has been honored with six certiﬁcates for new
drugs, one clinical approval document for her new drug and two
invention patents. In the ﬁeld of traditional Chinese medicine,
the study of A. annua L. was conducted systematically, and its
medicinal varieties are normalized. “Medicines without
confusing names beneﬁt people”, the work conducted by herteam improves the control level of the qualities of original crude
drugs and decoction pieces and corrects the long-used mistake of
Chinese Pharmacopoeia. For over 40 years, Youyou Tu has
worked hard in her ﬁeld and obtained great achievements, so the
Nobel Prize in Physiology or Medicine she won is a fully
deserved recognition of her achievements.
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